Comparing the effect of probiotic and conventional yoghurt consumption in patients with non-alcoholic fatty liver disease (NAFLD)

Comparing the effect of probiotic and conventional yoghurt consumption on serum level of adiponectin in patients with non-alcoholic fatty liver disease (NAFLD)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201210313664N8

Enrollment

Registered

2012-11-28

Start date

2012-06-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver disease (NAFLD). nonalcoholic steatohepatitis

Interventions

Intervention 1: Intervention group: 300 g probiotic yogurt. Intervention 2: Placebo group: 300 g conventional yoghurt.

Intervention group: 300 g probiotic yogurt

Placebo group: 300 g conventional yoghurt

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients who agree to participate in the study ; Women aged 20-50 years (premenopausal) and in men 20-65 years; BMI range between 25 to 40 kg/ m2; suffering from Nonalcoholic fatty liver disease Exclusion criteria: suffering from gastrointestinal disease; diabetes and rheumatoid arthritis; Receiving Antibiotics during the two weeks before the study and during the study; Follow the diet and weight loss; Receiving Supplements of vitamins, antioxidants, fiber and omega-3 within 3 weeks before baseline and during the study; presence of pregnancy or lactation or menopause; taking Contraceptive drugs; Liver transplantation; alcohol intake; any cause of chronic liver disease other than NAFLD such as testing positive for hepatitis B, hepatitis C and autoimmune hepatitis – Immune; History of cancer and treatment; performing a complete intravenous feeding; rapid weight loss; cut part of the intestine and Gastropathy; drugs such as corticosteroids, amiodarone, tamoxifen, cyclins, perhexiline, methotrexate, aspirin, and hydralazine;presence of inherited Hemochromatosis (transferrin saturation greater than 45%) and Wilson's disease; Cholestatic liver disease; advanced liver disease; heart failure; thyroid (abnormal TSH) and renal disease; gastric bypass surgery; cachexia

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Adiponectin. Timepoint: Baseline and at the end of intervention. Method of measurement: ELISA.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVice-chancellor for research-Tabriz University of Medical Science

Tabriz university of medical science

ostadrahimia@tbzmed.ac.ir+98 41 1335 7311

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026